1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,077 | 0,119 | 11:43 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08:30 | Intervacc AB: Interim report January - June 2026 | 58 | GlobeNewswire (Europe) | THE GROUP IN SUMMARY
THE GROUP
APRIL - JUNE
JAN - JUNE
FULL YEAR
2026
2025
2026
2025
2025
Net... ► Artikel lesen | |
| 30.07. | Intervacc AB: Intervacc submits Type II variation to EMA seeking 12-month duration of immunity for Strangvac | 201 | GlobeNewswire (Europe) | Intervacc AB (publ) today announces that it has submitted a Type II variation application to the European Medicines Agency (EMA) for Strangvac, the company's innovative vaccine against strangles in... ► Artikel lesen | |
| 29.07. | Intervacc AB: Intervacc makes first export of Strangvac to New Zealand under Special Circumstances Permit | 392 | GlobeNewswire (Europe) | Intervacc AB (publ) today announces that Strangvac, the company's innovative vaccine against strangles in horses, has been approved for import into New Zealand under a Special Circumstances Permit.... ► Artikel lesen | |
| 22.05. | Intervacc AB: Intervacc completes successful evaluation of US strain of strangles pathogen ahead of clinical trials | 188 | GlobeNewswire (Europe) | Intervacc AB (publ), a Swedish growth company specialising in animal vaccines, has completed the evaluation of a US strain of Streptococcus equi in US horses prior to its use in a clinical trial towards... ► Artikel lesen | |
| 15.05. | Emil Billbäck appointed new Chair of the Board of Intervacc | 2 | Cision News | ||
| 13.05. | Intervacc AB: Report from Annual General Meeting in Intervacc | 190 | GlobeNewswire (Europe) | Intervacc AB (publ) held its Annual General Meeting ("AGM") on Wednesday 13 May 2026, at which the following resolutions were made.
Adoption of the income statement and balance sheet
The AGM adopted... ► Artikel lesen | |
| 13.05. | Intervacc AB Q1 Sales Decline | 1 | RTTNews | ||
| 12.05. | Intervacc AB: Intervacc strengthens management team for future growth | 278 | GlobeNewswire (Europe) | Intervacc AB (publ), a Swedish growth company in animal health with the vaccine Strangvac registered on 16 European markets, today announces that the company is strengthening its management team through... ► Artikel lesen | |
| INTERVACC Aktie jetzt für 0€ handeln | |||||
| 12.05. | Intervacc AB: Interim report January - March 2026 | 213 | GlobeNewswire (Europe) | The Group in summary
01/01/26
01/01/25
01/01/25
-31/03/26
-31/03/25
-31/12/25
Net... ► Artikel lesen | |
| 04.05. | INTERVACC AB: International Awareness Initiative Against Strangles | 2 | Cision News | ||
| 23.04. | Intervacc brings together leading US and European experts to jointly tackle strangles | 2 | Cision News | ||
| 16.04. | Intervacc AB: Unprecedented decision opens the way for the launch of Strangvac in Iceland | 219 | GlobeNewswire (Europe) | Intervacc AB (publ) announces that Strangvac, the company's innovative vaccine against strangles in horses, has been approved by the authorities in Iceland.
Strangles, a potentially lethal infection... ► Artikel lesen | |
| 14.04. | Intervacc publishes the 2025 Annual Report | 1 | Cision News | ||
| 10.04. | Notice of Annual General Meeting in Intervacc AB (publ) | 1 | Cision News | ||
| 19.03. | Intervacc AB: Intervacc announces breakthrough protection against Streptococcus suis infection in piglets | 253 | GlobeNewswire (Europe) | Intervacc AB (publ) is first in the world to show that piglets were protected against the virulent and severe disease-causing S. suis Sequence Types 1 and 16 (serotype 2 and 9, respectively), by vaccinating... ► Artikel lesen | |
| 09.03. | Intervacc presents to the capital market on three occasions in March | 2 | Cision News | ||
| 17.02. | Intervacc AB: Year-end report January - December 2025 | 302 | GlobeNewswire (Europe) | The Group in summary
01/10/25
01/10/24
Full year
Full year
-31/12/25
-31/12/24
2025
2024
Net... ► Artikel lesen | |
| 05.02. | Intervacc AB: Intervacc announces change of CEO | 365 | GlobeNewswire (Europe) | The Board of Directors of Intervacc AB (publ), together with Jonas Sohlman, has agreed that he will leave his role as Chief Executive Officer and Group CEO.
Simultaneously, the Board has appointed... ► Artikel lesen | |
| 16.12.25 | Intervacc AB: Clinical studies with Strangvac have begun in the U.S. market | 241 | GlobeNewswire (Europe) | Intervacc AB (publ) announces that the company has started the first phase of clinical safety studies in horses in the United States as part of the approval process for Strangvac in the U.S.
The initial... ► Artikel lesen | |
| 19.11.25 | Intervacc AB: Interim report January - September 2025 | 237 | GlobeNewswire (Europe) | The Group in summary
01/07/25
01/07/24
01/01/25
01/01/24
Full year
-30/09/25
-30/09/24
-30/09/25
-30/09/24
2024
Net... ► Artikel lesen |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NANOREPRO | 1,900 | 0,00 % | EQS-DD: NanoRepro AG: Dr. Olaf Stiller, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
18.08.2026 / 07:30... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 10,190 | +0,10 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| BRAIN BIOTECH | 2,840 | +2,53 % | Brain Biotech: Sven K. Weber wird neuer Vorstandsvorsitzender | Der Aufsichtsrat der Brain Biotech AG hat Sven K. Weber zum 1. Oktober 2026 für drei Jahre zum neuen Vorstandsvorsitzenden bestellt. Der 44-Jährige war seit 2011 in verschiedenen Führungspositionen... ► Artikel lesen | |
| AAP IMPLANTATE | 1,470 | +1,38 % | EQS-News: aap Implantate AG: aap verbessert Profitabilität im ersten Halbjahr 2026 und startet mit Rekordauftragseingang in die zweite Jahreshälfte | EQS-News: aap Implantate AG
/ Schlagwort(e): Halbjahresbericht/Halbjahresergebnis
aap verbessert Profitabilität im ersten Halbjahr 2026 und startet mit Rekordauftragseingang in... ► Artikel lesen | |
| CO.DON | 0,014 | -34,15 % | EQS-AFR: CO.DON AG i.l.: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: CO.DON AG i.l.
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
CO.DON AG i.l.: Vorabbekanntmachung über die... ► Artikel lesen | |
| BIOXXMED | 1,000 | 0,00 % | PTA-News: bioXXmed AG: Einladung zur Hauptversammlung | DJ PTA-News: bioXXmed AG: Einladung zur Hauptversammlung
Unternehmensmitteilung für den Kapitalmarkt
bioXXmed AG: Einladung zur Hauptversammlung
Heidelberg (pta000/20.07.2026/15:45... ► Artikel lesen | |
| CLINUVEL | 6,372 | +5,88 % | CLINUVEL PHARMACEUTICALS LIMITED: CLINUVEL Annual Results - Investor Webinar | ||
| SANGAMO THERAPEUTICS | 0,126 | -100,00 % | SANGAMO THERAPEUTICS, INC - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | ||
| BIO-GATE | 2,780 | 0,00 % | EQS-Adhoc: Bio-Gate AG: Bio-Gate schließt Kapitalerhöhung aus genehmigtem Kapital sowie Bezugsrechtsemmission ab | EQS-Ad-hoc: Bio-Gate AG / Schlagwort(e): Kapitalmaßnahmen / Kapitalerhöhung
Bio-Gate AG schließt Kapitalerhöhung aus genehmigtem Kapital sowie Bezugsrechtsemmission ab... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 4,830 | +12,85 % | COSCIENS Biopharma Inc. Reports Q2 2026 Results | TORONTO, ONTARIO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCI.F) ("COSCIENS" or the "Company") today reported its financial and operating results for the second... ► Artikel lesen | |
| SCORPIUS | - | - | Antares Global launches Scorpius MGA platform under Ian Morris | ||
| EDITAS MEDICINE | 2,690 | -3,24 % | Editas Medicine, Inc.: Editas Medicine Announces Second Quarter 2026 Results and Business Updates | EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins,... ► Artikel lesen | |
| EXELIXIS | 47,130 | +1,16 % | BMO initiates Exelixis stock at Market Perform, cites patent cliff | ||
| EVONEXT | 2,540 | -3,05 % | Adhoc: EvoNext Holdings SA: EvoNext Holdings SA confirms advanced discussions on a reverse merger with Ascend Sport Technology AG | EvoNext Holdings SA / Key word(s): Merger
EvoNext Holdings SA confirms advanced discussions on a reverse merger with Ascend Sport Technology AG
17-Aug-2026 / 17:50 CET/CEST
Release of... ► Artikel lesen | |
| GERON | 1,392 | +2,50 % | Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
INTERVACC AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -3,45 % bei einem Aktienkurs von 0,081 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INTERVACC AB finden Sie auf Wallstreet Online.